Biocept Blood-Based Test for Prostate Cancer and Breast Cancer

Biocept has launched a CLIA-validated androgen receptor expression assay that uses a patient's blood to detect and monitor late-stage prostate cancer and a certain form of breast cancer. The assay uses circulating tumor cells from a simple blood draw to detect androgen receptor expression, which is prevalent in patients with advanced prostate cancer. The androgen receptor is also found in a subset of patients with estrogen receptor-negative, progesterone receptor-negative and Her2-negative breast cancer, known as triple negative breast cancer.